PET radiopharmaceuticals in radiation treatment planning - synthesis and biological characteristics.

Roland Haubner

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2010;96(3):280-7

PMID: 20724013

Abstract

During the last decade several different PET radiopharmaceuticals entered into the clinic and positron emission tomography (PET) became an important tool for staging of cancer patients and assessing response to therapy. Meanwhile FDG-PET has also found application in radiation treatment planning. Potential radiopharmaceuticals for radiation treatment planning may also include tracers allowing monitoring of proliferation, amino acid metabolism, hypoxia, lipid metabolism and receptor expression. Here the syntheses of a selection of clinically tested promising tracers are summarized and the different molecular mechanisms for accumulation are discussed which may help to choose the appropriate tracer for planning radiation treatment strategies.

Copyright 2010 European Society for Therapeutic Radiology and Oncology and European Association of Nuclear Medicine. Published by Elsevier Ireland Ltd.. All rights reserved.

Address: Medizinische Universität Innsbruck, Innsbruck, Austria. [email protected]
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.